USPTO Examiner BADIO BARBARA P - Art Unit 1628

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18616762NEUROACTIVE STEROIDS AND THEIR METHODS OF USEMarch 2024October 2024Allow710YesNo
18616903NEUROACTIVE STEROIDS AND THEIR METHODS OF USEMarch 2024October 2024Allow710NoNo
18610777SOLID STATE FORMS OF MAVACAMTEN AND PROCESS FOR PREPARATION THEREOFMarch 2024January 2025Allow1031YesNo
183855821-(4-BROMOBENZYLIDENEAMINO)-5-PHENYLIMIDAZOLIDINE-2,4-DIONE AS AN ANTIMICROBIAL COMPOUNDOctober 2023April 2024Allow510NoNo
183847681-[4,5-BIS(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOL-2-YL]-2-NAPHTHOL AS AN ANTIMICROBIAL COMPOUNDOctober 2023March 2024Allow410NoNo
183845994,5-BIS(4-BROMOPHENYL)-1-HEXYL-2-(4-NITROPHENYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUNDOctober 2023March 2024Allow510NoNo
183788182-(BENZO[D]THIAZOL-2-YL)-N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDOctober 2023January 2024Allow310NoNo
18334124NEUROACTIVE STEROIDS AND THEIR METHODS OF USEJune 2023January 2024Allow720NoNo
18334189NEUROACTIVE STEROIDS AND THEIR METHODS OF USEJune 2023September 2023Allow310NoNo
18334209NEUROACTIVE STEROIDS AND THEIR METHODS OF USEJune 2023September 2023Allow310NoNo
18196956THERAPEUTIC FORMULATIONS AND USES THEREOFMay 2023June 2024Abandon1320YesNo
18143166BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOFMay 2023December 2024Allow2010NoNo
18295091FARNESOID X RECEPTOR MODULATORSApril 2023August 2024Abandon1710NoNo
18128021Methods of Treatment of Inflammation Related Conditions Using Pluripotent Anti-Inflammatory and Metabolic ModulatorsMarch 2023May 2024Abandon1410NoNo
18175812CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTSFebruary 2023June 2024Allow1520NoNo
18111161HEXADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHRENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATIONFebruary 2023May 2024Abandon1510NoNo
18169964COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERSFebruary 2023August 2024Allow1820NoNo
18157777COMPOUND AND METHOD FOR THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE CONDITIONSJanuary 2023May 2024Abandon1610NoNo
18153160THERAPEUTIC DNP DERIVATIVES AND METHODS USING SAMEJanuary 2023August 2024Allow1920NoNo
18080041COMPOSITIONS AND METHODS FOR TREATING CANCERDecember 2022December 2024Allow2430YesNo
18059533Modified Tetracycline for Treatment of Alcohol Use Disorder, Pain and Other Disorders Involving Potential Inflammatory ProcessesNovember 2022September 2024Allow2120NoNo
17977920NONRACEMIC MIXTURES AND USES THEREOFOctober 2022July 2024Allow2110NoNo
18050730METHODS FOR ASSEMBLY OF TETRACYCLIC COMPOUNDS BY STEREOSELECTIVE C9-C10 BOND FORMATIONOctober 2022April 2024Allow2610NoNo
17959592COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERSOctober 2022November 2023Allow1400NoNo
17952694NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOFSeptember 2022April 2024Allow1810NoNo
17951129STEROIDAL PIPERIDONE DERIVATIVE, SYNTHESIS METHOD, AND USE THEREOFSeptember 2022July 2023Allow1010NoNo
17929273COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASESeptember 2022March 2023Allow610NoNo
17893399CONDUCTING REACTIONS IN LEIDENFROST-LEVITATED DROPLETSAugust 2022September 2024Allow2510NoNo
17806322CRYSTALLINE FORMS OF VAMOROLONEJune 2022August 2023Abandon1410NoNo
17749976OXYSTEROLS AND METHODS OF USE THEREOFMay 2022July 2024Abandon2620NoNo
17725331USE OF OUABAIN ANTAGONISTS TO INHIBIT VIRAL INFECTIONApril 2022March 2024Abandon2310NoNo
17718915C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDSApril 2022March 2024Abandon2310NoNo
17714996PHARMACEUTICAL COMBINATION COMPRISING AN ALK INHIBITOR AND A SHP2 INHIBITORApril 2022March 2024Allow2301NoNo
17713759THERAPEUTIC DNP DERIVATIVES AND METHODS USING SAMEApril 2022October 2022Allow710NoNo
17711891METHODS AND COMPOSITIONS FOR STIMULATION OF THE INTESTINAL ENTEROENDOCRINE SYSTEM FOR TREATING DISEASES OR CONDITIONS RELATED TO THE SAMEApril 2022May 2024Abandon2501NoNo
17708159PROCESS FOR THE PREPARATION OF CORTEXOLONE 17alpha-PROPIONATE AND NEW HYDRATED CRYSTALLINE FORM THEREOFMarch 2022December 2024Allow3240YesNo
17707303NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOFMarch 2022June 2024Allow2720YesNo
17703877COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF PARKINSON'S DISEASEMarch 2022December 2023Abandon2110NoNo
17703331GANAXOLONE FOR USE IN TREATING GENETIC EPILEPTIC DISORDERSMarch 2022August 2023Abandon1730YesNo
17703068CANNABINOID PRODRUG COMPOUNDSMarch 2022January 2024Allow2241YesNo
17700943GLUCOCORTICOID RECEPTOR AGONISTSMarch 2022June 2023Allow1420NoNo
17700824CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTSMarch 2022November 2022Allow800NoNo
17680553Combination Therapy For Prostate CancerFebruary 2022March 2024Abandon2410NoNo
17592985PROCESS FOR THE PREPARATION OF FULVESTRANTFebruary 2022February 2024Abandon2430NoNo
17575731NOVEL TRICYCLIC COMPOUNDSJanuary 2022March 2024Abandon2601NoNo
17564400FORMULATIONS AND METHODS FOR PROVIDING PROGESTIN-ONLY CONTRACEPTIONDecember 2021February 2024Abandon2510NoNo
17554808HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERSDecember 2021September 2024Abandon3321NoNo
17547496Liver DiseaseDecember 2021September 2023Abandon2220YesYes
17539213METHOD FOR PREPARING 7ALPHA-METHYL-19-ALDEHYDE-4-ANDROSTENE-3,17-DIONE BY ELECTROCATALYTIC OXIDATIONDecember 2021December 2022Allow1310NoNo
17455538ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVESNovember 2021November 2023Allow2310NoNo
17609627IRRADIATION PROCESS OF PRO VITAMIN DNovember 2021August 2024Allow3421NoNo
17513733NON-INFECTIVE NASAL SYMPTOM MANAGEMENT COMPOSITIONS AND METHODSOctober 2021June 2024Abandon3251NoNo
17506559TREATMENT OF HYPERAMMONEMIA IN PATIENTS WITH RENAL INSUFFICIENCYOctober 2021November 2022Abandon1320NoNo
17506561TREATMENT OF HYPERAMMONEMIA IN PATIENTS WITH RENAL INSUFFICIENCYOctober 2021November 2022Abandon1320NoNo
17504177COMBINATION THERAPY FOR THE TREATMENT OF CANCEROctober 2021October 2023Abandon2410NoNo
17470905DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONISTSeptember 2021December 2023Abandon2710NoNo
17058518Preparation Method of Vascular Leakage Blockers With a High YieldSeptember 2021May 2022Allow1820NoNo
17412328METHODS AND COMPOSITIONS FOR TREATING ROSACEAAugust 2021December 2023Abandon2810NoNo
17405984Testosterone Ester Triglyceride FormulationsAugust 2021June 2024Allow3430NoNo
17403899Bio-catalyzed Synthesis of New Aromatase Inhibitors through Structural Modifications of Anticancer Drug FormestaneAugust 2021February 2023Abandon1810NoNo
17399105METHODS OF MAKING CHOLIC ACID DERIVATIVES AND STARTING MATERIALS THEREFORAugust 2021March 2022Allow820NoNo
17398121METHOD FOR ENHANCING EXPRESSION OF MOISTURIZING-RELATED SUBSTANCE IN EPIDERMISAugust 2021January 2024Abandon2910YesNo
174445942,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOFAugust 2021August 2023Allow2510NoNo
17396034OXYSTEROLS AND METHODS OF USE THEREOFAugust 2021June 2023Allow2210NoNo
17396464A CRYSTALLINE 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDAugust 2021August 2023Allow2420NoNo
17392004NEUROSTERIOD DERIVATIVES AND USES THEREOFAugust 2021September 2024Abandon3721NoNo
17381829NEUROACTIVE STEROIDS AND METHODS OF USE THEREOFJuly 2021August 2023Allow2520NoNo
17373771SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORSJuly 2021March 2024Allow3220NoNo
17360614PROGESTERONE PHOSPHATE ANALOGS AND USES RELATED THERETOJune 2021March 2023Allow2110NoNo
173047782,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOFJune 2021April 2024Allow3320YesYes
17350888HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERSJune 2021November 2021Allow510NoNo
17351176OTIC GEL FORMULATIONS FOR TREATING OTITIS EXTERNAJune 2021November 2023Abandon2810NoNo
17341106A2A ANTAGONISTS AS COGNITION AND MOTOR FUNCTION ENHANCERSJune 2021April 2023Abandon2210NoNo
17319545INTERMEDIATES FOR THE PREPARATION OF 11-METHYLENE STEROIDSMay 2021October 2024Allow4110NoNo
17307699METHOXYCHALCONE DERIVATIVES AND USES THEREOFMay 2021November 2023Abandon3120NoNo
17244348METHODS OF TREATING PAINApril 2021December 2024Allow4420NoYes
17239685TOPICAL COMPOSITIONS OF DUTASTERIDEApril 2021October 2023Allow3040NoNo
172865249(11)-UNSATURATED NEUROACTIVE STEROIDS AND THEIR METHODS OF USEApril 2021December 2024Abandon4330NoNo
17231432COMPOSITIONS AND METHODS FOR PROFILING OF GUT MICROBIOTA-ASSOCIATED BILE SALT HYDROLASE (BSH) ACTIVITYApril 2021September 2024Allow4131NoNo
17228819FARNESOID X RECEPTOR MODULATORSApril 2021April 2023Abandon2410NoNo
1728274411,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAINApril 2021July 2024Allow4010NoNo
17219940Treatment RegimenApril 2021February 2024Abandon3430NoNo
17217187Methods of Treatment of Inflammation Related Conditions Using Pluripotent Anti-Inflammatory and Metabolic ModulatorsMarch 2021April 2023Abandon2410NoNo
17277917CH24H INHIBITORS FOR PAIN USEMarch 2021August 2024Abandon4110NoNo
17199506OCULAR FORMULATIONS FOR DRUG-DELIVERY TO THE POSTERIOR SEGMENT OF THE EYEMarch 2021June 2024Abandon3910NoNo
17192634COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1March 2021July 2024Abandon4101NoNo
17186447Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use ThereofFebruary 2021February 2023Allow2310NoNo
17186272Intermediates for the Synthesis of Bile Acid Derivatives, in Particular of Obeticholic AcidFebruary 2021June 2022Allow1610NoNo
17272091C19 SCAFFOLDS AND STEROIDS AND METHODS OF USE AND MANUFACTURE THEREOFFebruary 2021June 2023Allow2711NoNo
17178026PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOFFebruary 2021June 2023Allow2810NoNo
17265577COMPOSITION FOR IMPROVING INTESTINAL ENVIRONMENT AND METHOD FOR IMPROVING INTESTINAL FLORAFebruary 2021May 2024Abandon3910NoNo
17164556COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASEFebruary 2021March 2023Allow2610NoNo
17161920NOVEL SALTS AND POLYMORPHS OF SCY-078January 2021May 2024Abandon3910NoNo
17262915FLUORINATED BILE ACID DERIVATIVESJanuary 2021August 2022Allow1820NoNo
17154175Methods of Treating Steroid Resistant Diseases and ConditionsJanuary 2021October 2023Abandon3320NoNo
17147957Aqueous gel composition and its useJanuary 2021June 2023Allow2910NoNo
17134241PLEUROMUTILIN URSODEOXYCHOLIC ACID ESTER WITH ANTIBACTERIAL ACTIVITY AND A METHOD OF PREPARING THE SAMEDecember 2020October 2021Allow1010YesNo
17122647CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3BETA-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVERS DISEASES AND ATHEROSCLEROSISDecember 2020March 2023Abandon2710NoNo
16973896Modified Tetracycline for Treatment of Alcohol Use Disorder, Pain and Other Disorders Involving Potential Inflammatory ProcessesDecember 2020August 2022Allow2020YesNo
17115095PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCERDecember 2020December 2022Allow2410YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BADIO, BARBARA P.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
38
Examiner Affirmed
20
(52.6%)
Examiner Reversed
18
(47.4%)
Reversal Percentile
68.5%
Higher than average

What This Means

With a 47.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
165
Allowed After Appeal Filing
41
(24.8%)
Not Allowed After Appeal Filing
124
(75.2%)
Filing Benefit Percentile
30.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 24.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BADIO, BARBARA P - Prosecution Strategy Guide

Executive Summary

Examiner BADIO, BARBARA P works in Art Unit 1628 and has examined 1,099 patent applications in our dataset. With an allowance rate of 51.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.

Allowance Patterns

Examiner BADIO, BARBARA P's allowance rate of 51.4% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BADIO, BARBARA P receive 2.25 office actions before reaching final disposition. This places the examiner in the 76% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BADIO, BARBARA P is 31 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +25.7% benefit to allowance rate for applications examined by BADIO, BARBARA P. This interview benefit is in the 76% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 17.1% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 40.9% of cases where such amendments are filed. This entry rate is in the 55% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 70.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 56% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 64.5% of appeals filed. This is in the 39% percentile among all examiners. Of these withdrawals, 63.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 62.3% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.2% of allowed cases (in the 84% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.2% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.